TRINETRA › Sectors › Healthcare
Anthem Biosciences Limited (ANTHEM) — share price, P/E and fundamentals
Anthem Biosciences Limited (NSE: ANTHEM) closed at ₹829.90 on 30 Oct 2026, +9.5% over one year, against a 52-week range of ₹579.15 – ₹977.55.
In the quarter ended 30 Jun 2026 (consolidated, filed 21 Jul 2026) it reported revenue of ₹418 cr and net profit of ₹120 cr, a 28.7% net margin; revenue fell 22.6% and profit fell 22.4% year on year.
On four consecutive filed quarters its trailing P/E is 81.2.
From the balance sheet dated 31 Mar 2026: return on equity 15.8%, ROCE 18.8%, debt-to-equity 0.02.
Against 65 Healthcare peers on NSE: Net margin higher than 95% of 63 sector peers; PBT margin higher than 90% of 63 sector peers; ROE higher than 62% of 63 sector peers.
Key figures
| Last close | ₹829.90 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -6.3% / +12.2% / +9.5% |
| 52-week low – high | ₹579.15 – ₹977.55 |
| Market capitalisation | ₹46,755 cr |
| Trailing P/E | 81.2 |
| Price / book | 15.37 |
| EV / EBITDA | 50.2 |
| Earnings yield | 1.2% |
| TTM EPS | ₹10.22 |
| TTM net profit | ₹576 cr |
| Quarter revenue | ₹418 cr |
| Quarter net profit | ₹120 cr |
| Net margin | 28.7% |
| Revenue growth (YoY) | -22.6% |
| Profit growth (YoY) | -22.4% |
| Return on equity | 15.8% |
| ROCE | 18.8% |
| Debt / equity | 0.02 |
| Current ratio | 5.54 |
| Free cash flow | ₹633 cr |
| Average daily turnover (50 days) | ₹42.8 cr |
Against Healthcare peers
| Metric | ANTHEM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 28.68 | 12.67 | 95 |
| PBT margin | 34.57 | 17.57 | 91 |
| ROE | 15.77 | 13.86 | 62 |
| ROCE | 18.75 | 16.59 | 64 |
| Debt / equity | 0.02 | 0.11 | 34 |
| Cash conversion | 1.43 | 1.25 | 65 |
| Trailing P/E | 81.18 | 43.07 | 83 |
| P/B | 15.37 | 5.88 | 90 |
Questions
What is the P/E ratio of Anthem Biosciences Limited?
Anthem Biosciences Limited's trailing P/E is 81.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026.
What were Anthem Biosciences Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Anthem Biosciences Limited reported revenue of ₹418 cr and net profit of ₹120 cr (consolidated), filed with the exchange on 21 Jul 2026.
What is Anthem Biosciences Limited's ROE?
Return on equity is 15.8% based on the balance sheet dated 31 Mar 2026.
Does Anthem Biosciences Limited have debt?
Debt-to-equity is 0.02 on the balance sheet dated 31 Mar 2026.
What is ANTHEM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ANTHEM traded between ₹579.15 and ₹977.55.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.